Enable Injections Partners with ARespo Biopharma on On-Body Delivery of Alpha-1 Antitrypsin Therapies
Key Points
- Enable Injections has partnered with ARespo Biopharma to use its enFuse on-body delivery technology in development programs for Alpha-1 Antitrypsin Deficiency.
- The enFuse system delivers large-volume biologic and small-molecule drugs subcutaneously as an alternative to intravenous administration, with potential at-home and self-administration options.
- The collaboration aims to improve treatment convenience and the overall patient experience for people living with this rare genetic disorder.
Enable Injections has entered into a strategic partnership with ARespo Biopharma to incorporate its enFuse on-body drug delivery technology into selected development programs targeting Alpha-1 Antitrypsin Deficiency (AATD). The collaboration will combine ARespo’s development of next-generation Alpha-1 Antitrypsin (AAT) therapies with Enable’s commercially approved drug delivery platform. The companies aim to explore how the technology could support treatment administration while improving convenience and the overall patient experience for individuals living with the rare genetic disorder.
ARespo is initially focused on developing replacement therapies for AATD, a condition in which the body does not produce sufficient functional Alpha-1 Antitrypsin protein. The company is pursuing treatment approaches intended to address existing limitations in care and improve clinical outcomes.
“At ARespo, we are committed to advancing innovative treatments for Alpha-1 Antitrypsin Deficiency, where significant unmet patient needs remain,” says Jay Mohr, CEO and Co-founder of ARespo Biopharma. He adds that access to Enable’s established delivery technology aligns with the company’s goal of developing therapies that can improve treatment convenience and quality of life for patients and their families.
Enable’s enFuse On-Body Delivery System is designed to administer large-volume doses of biologic and small-molecule drugs through subcutaneous delivery. The wearable system is intended to provide an alternative to intravenous administration, potentially allowing patients to receive treatment outside traditional healthcare settings, including at home. The technology is designed around a discreet, comfortable and straightforward administration experience, with flexible options for where patients receive their medications and the potential for self-administration. For ARespo, integrating an on-body delivery option into its development programs could offer another way to address the treatment burden associated with chronic AATD replacement therapy.
Michael D. Hooven, Chairman and CEO of Enable Injections, says the partnership reflects a shared interest in developing therapies with patient needs and treatment administration in mind. He notes that rare disease populations can face distinct challenges related to treatment availability and administration, creating opportunities for drug delivery technologies to contribute to the overall treatment experience.
Visit enableinjections.com for more information.
Total Page Views: 1

















